Results 171 to 180 of about 3,715,994 (387)

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Corrigendum: G-CSF does not influence C2C12 myogenesis despite receptor expression in healthy and dystrophic skeletal muscle

Frontiers in Physiology, 2017
Craig R. Wright, Erin L. Brown, Paul A. Della-Gatta, Alister C. Ward, Gordon S. Lynch, Aaron P. Russell   +5 more
doaj   +1 more source

Cryo-EM structure of the extracellular domain of murine Thrombopoietin Receptor in complex with Thrombopoietin

Nature Communications
Thrombopoietin (Tpo) is the primary regulator of megakaryocyte and platelet numbers and is required for haematopoetic stem cell maintenance. Tpo functions by binding its receptor (TpoR, a homodimeric Class I cytokine receptor) and initiating cell ...
Kaiseal T. G. Sarson-Lawrence, Joshua M. Hardy, Josephine Iaria, Dina Stockwell, Kira Behrens, Tamanna Saiyed, Cyrus Tan, Leila Jebeli, Nichollas E. Scott, Toby A. Dite, Nicos A. Nicola, Andrew P. Leis, Jeffrey J. Babon, Nadia J. Kershaw   +13 more
doaj   +1 more source

NFAT1 and NFκB regulates expression of the common γ-chain cytokine receptor in activated T cells. [PDF]

Cell Commun Signal, 2023
Shim JA, Lee SM, Jeong JW, Kim H, Son WJ, Park JH, Song P, Im SH, Bae S, Park JH, Jo Y, Hong C.   +11 more
europepmc   +1 more source

The Common Cytokine Receptor γ Chain Family of Cytokines.

Cold Spring Harbor Perspectives in Biology, 2018
Jian-Xin Lin, W. Leonard
semanticscholar   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Daratumumab Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Case Report

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune‐mediated neuropathy featuring progressive weakness, sensory deficits, and areflexia. While corticosteroids, intravenous immunoglobulin, and plasmapheresis are effective first‐line immunotherapies, a subset of patients remains treatment‐refractory.
Xueyu Zhang, Jianli Zhao, Xue Zhao, Xiaowei Hu, Zichun Xiao, Jie Wu, Xiaowen Li, Jing Xu, Yu‐Jing Li   +8 more
wiley   +1 more source

Hybrid tyrosine kinase/cytokine receptors transmit mitogenic signals in response to ligand.

, 1994
Robert E. Pacifici, A R Thomason
openalex   +1 more source

Enhancement of Toll-like receptor 2-mediated immune responses by AIMP1, a novel cytokine, in mouse dendritic cells [PDF]

, 2011
Eugene Kim, Hye-Jin Hong, Daeho Cho, Jung Min Han, Sung‐Hoon Kim, Tae Sung Kim   +5 more
openalex   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source